Lexaria completes patient dosing in Phase 1b GLP-1 study
Tweet Send to a Friend
Lexaria Bioscience Corp. (NASDAQ: LEXX) announced its contract research organization completed the last patient last visit milestone in the company's ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


